CPCR Assistant Professor, Dr. Brandon Weiss, joins Disabled American Veterans for an interview exploring the current research on psychedelic treatments for Veteran mental health conditions like PTSD
youtu.be/iKlLOn6XHHY?...
In clinical settings, facilitators can meaningfully shape patients’ experiences, which may carry into therapeutic effects.
Check out the full paper here: www.sciencedirect.com/science/arti...
Psychedelic session facilitators play an important role in supporting participants before, during, and after psychedelic administration sessions. CPCR researchers and collaborators analyzed the largest dataset of its kind, featuring 20+ years of psilocybin trials from Johns Hopkins.
The findings harmonize years of research while providing a map for future drug-specific discovery. 🧠🧪
Read the full paper here: www.nature.com/articles/s41...
And New York Times coverage here: www.nytimes.com/2026/04/07/h...
Crucially, while the study establishes a reliable, cross-drug neural signature, it also points toward subtle differences between individual compounds—opening new doors for personalized psychedelic medicine.
Spanning 5 drugs (psilocybin, LSD, DMT, mescaline, ayahuasca) and 11 datasets, the research reveals the "common denominators" of how these substances reshape neural communication.
How do psychedelics alter brain activity? 🍄✨
A landmark study published this week in @NatureMedicine by CPCR researchers @FredBarrettPhD, @winstonian3 and a global team of collaborators analyzes the largest human psychedelic fMRI dataset to-date.
Join us Wednesday for the Psychedelic Archives Project Guest Speaker Series!
🎤 Jeffrey Breau, MDiv.
🗓 April 15, 2026 | ⏰ 4:30 PM EDT
🎟 Free to attend — sign up at the link below and in our bio!👇
jhubluejays.zoom.us/j/92622903856
Have you had separate experiences with psychedelics and cannabis? If so, take our survey! tinyurl.com/psyches-cann...
Your responses help us understand these compounds better, so that we can continue to expand the science of psychedelics and knowledge about their risks and benefits.
www.youtube.com/watch?v=_K8J...
Thanks Dr. Chuck Nichols for presenting at the CPCR journal club! Watch Dr. Nichols' full presentation on using preclinical models to investigate the therapeutic potential of psychedelics 🔗👇
CPCR Faculty David Yaden was quoted in the New Yorker on one of the more interesting scientific questions in the field of psychedelics - what role (if any) the psychedelic experience has in their persisting effects www.newyorker.com/culture/anna...
It's not too late to sign up for our upcoming continuing education course on March 26th! Learn from our expert faculty and earn up to 6.5 CE/CMEs
Wondering what clinicians should know about psychedelic-assisted treatments? tinyurl.com/hopkinscme
Join our upcoming CME/CE course designed to help clinicians engage with patients, understand new research, and prepare for the future of psychedelic-assisted care.
New findings from a pilot randomized trial of psilocybin for smoking cessation are now published in JAMA Open Network — this is one of the largest controlled trials of psilocybin for substance use disorder, with promising results! jamanetwork.com/journals/jam...
Thrilled to announce our new CME course on psychedelic medicine, taught by CPCR faculty!
Designed for physicians, advanced practice providers, mental health clinicians, & anyone interested in psychedelic medicine.
✔ Up to 6.5 CME/CE credits
📅 March 27, 2026 | Live Online
🔗 tinyurl.com/hopkinscme
Ready for a weekend of science at the International Society for Research on Psychedelics (ISRP)
New pilot study from Johns Hopkins finds psilocybin-assisted treatment was associated with significant and sustained benefits in post-treatment Lyme disease, including improved mood, fatigue, sleep, pain, and quality of life for up to 6 months. More research is needed to confirm. Read more below 👇
Huge congratulations to Dr. Albert Garica-Romeu who was recently named a Frontiers of Science Fellow by the National Academy of Sciences! tinyurl.com/2cbkt93c
A new review in Psychiatric Times examines adverse event data for psilocybin, MDMA, ketamine, and ibogaine, finding meaningful differences in risk and inconsistent reporting. Clear compound-level distinctions are crucial as access expands.
www.psychiatrictimes.com/view/adverse...
Dr. Fred Barrett co-authored a new paper on the challenges of running rigorous psychedelic clinical trials — from expectancy effects to blinding. As therapies near FDA approval, strong science is essential.
Read more: journals.sagepub.com/doi/10.1177/...
🔬 We are hiring a Research Data Analyst. Learn more and apply: hiring.jhu.edu/careers?quer...
Dr. Brandon Weiss explores how MDMA and psilocybin may help rewire fear patterns in PTSD, including a new PAMVET trial on combining the two. Learn more below.www.livescience.com/health/mind/psychedelics...
CPCR Medical Director Dr. Sandeep Nayak weighs in on where psilocybin therapy for PTSD is headed – from policy shifts to clinical progress and what it means for the future of care www.lucid.news/legislation-...
We're excited to unveil our redesigned CPCR website! Whether you're interested in participating in cutting-edge clinical trials, exploring our research publications, or accessing information about our integration clinic and online courses. Check it out!
hopkinspsychedelic.org
Can psilocybin assisted therapy reduce opioid use and improve quality of life? We are seeking people near Baltimore, Maryland with Opioid Use Disorder to participate in a trial to see if psilocybin can reduce opioid use and improve quality of life. jhmi.co1.qualtrics.com/jfe/form/SV_...
The Psychedelic Archives Project Guest Speaker Series continues this Wednesday with Dr. Nicolas Langlitz.
🗓 February 11th, 2026 | ⏰ 4:30 PM EST
🎟 Attendance is free — registration link below 👇
jhubluejays.zoom.us/j/92622903856
Ongoing debate about psychological support versus psychotherapy in psychedelic trials often stems from vague definitions. Clarifying these constructs is essential for rigorous study of safety and efficacy.
